Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3793985 | 0.88 | ALDH1A1 (0.36) | ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL11827833 | 0.83 | ALDH1A1 (0.36) | ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL7869452 | 0.82 | — | — | |
| SCHEMBL2807323 | 0.82 | ALDH1A1 (0.41) | LMNAALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL22071625 | 0.79 | ALDH1A1 (0.35) | LMNAALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL12909256 | 0.78 | ALDH1A1 (0.31) | ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL11824553 | 0.77 | ALDH1A1 (0.32) | ALDH1A1TSHRMAPK1TDP1 | |
| SCHEMBL4247604 | 0.77 | — | — | |
| SCHEMBL687389 | 0.77 | — | — | |
| SCHEMBL11824940 | 0.76 | ALDH1A1 (0.34) | ALDH1A1TSHRMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285576-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | ELLIPSES PHARMA LTD (GB) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285576-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | PARP1, TOP1, PARP2 | LMNA 1474/4885ALDH1A1 536/4885TSHR 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.